Title and Abstract for the talk on 5/26/2015 in TCU by Jiann-Shiun Lai

 **The Impact of Therapeutic Antibody Developmental Trend to Taiwan Biotech Industry**

**以抗體藥物開發趨勢看台灣生技發展方向**

The use of recombinant monoclonal antibody on the diseases, especially on the therapeutic areas of inflammatory, autoimmune, cancer, and infectious diseases, has achieved considerable success for last decade. Nearly 50 antibodies have been successfully launched to the market for various indications. Tremendous benefit to patients has been gained with the first generation of therapeutic antibodies. Beyond improved generation and optimization technologies, the development of antibody therapeutics has being emerged more diversified into the clinical trials. These include bispecific, antibody-drug conjugates, and immune modulating targets, etc. Market analysis predicts growth for this market to be exceed USD 100 billion this coming year and is predicted to have a double digit growth of around 15% from the year 2015 to 2020. The government of Taiwan has introduced several action plans, especially the “Biotech and New Pharmaceutical Development Plan” and “Diamond Action Plan for Biotech Takeoff”, to support the development of the biotech industry in Taiwan. It has raised more than NT$100 billion biotech venture capital fund and 88 uplisting biotech companies in the stock market. Other than the capital investment, the success of the biotech industry is still relied on the success of the drug launched to the market. Key issues to boost the biotechnology industry will be discussed.